Phytoselective therapy is a method of choice for the treatment of mastopathy in combination with premenstrual syndrome




breast dishormonal diseases, premenstrual syndrome, Tazalok, Vitex agnus-castus


Breast dishormonal diseases and premenstrual syndrome (PMS) have a common pathogenetic mechanism: hyperprolactinemia, decreased progesterone levels, thyroid dysfunction, increased cortisol including as a result of stress, dysphoric disorders.

Purpose of the study was to optimize monotherapy of breast dishormonal diseases in combination with PMS with phytoselective complex Tazalok™ and to compare the clinical efficacy with traditional therapy with Vitex agnus-castus derivative.

Materials and methods. 120 women aged 22–39 years were observed into 2 groups: group I – 60 patients who received monotherapy Tazalok™ for 3 months; group II – 60 patients who received monotherapy with derivative of Vitex agnus-castus. Data analysis was performed after 1 and 3 months of treatment. Sex hormones, thyroid, gonadotropic hormones levels were determined. Ultrasound examination with color Doppler flow mapping of mammary glands, pelvic organs, and thyroid was performed. Dysphoric disorders were assessed on the Beck depression scale, pain was assessed on the visual-analog scale (VAS).

Results. Group I showed an improvement in hormonal profile, reduction of subjective complaints after 1 month, in group II there was mainly a decrease in prolactin and relative normalization of follicle-stimulating hormone, luteinizing hormone; PMS complaints persisted. By 3 months patients in group I had normalization of all hormonal parameters, including cortisol, thyroid hormones, decreased pathological vascularization of mammary glands, thyroid, and pelvic organs, and a significant reduction in the Beck depressive score and VAS. In group II there was no normalization of cortisol, thyroid hormones, significantly reduced levels of progesterone and luteinizing hormone compared to group I, there was pathological vascularization in the thyroid gland, uterus. Dysphoric disorders decreased slightly, pain syndrome on the VAS decreased moderately, but the score was higher than among women taking Tazalok™.

Conclusions. Tazalok™ directly affects reproductive system and balance of stress hormones, has a therapeutic effect on the thyroid gland. Under its action sonographic picture of hormone-dependent organs was normalized in contrast to the Vitex agnus-castus derivative. Tazalok™ has a pronounced effect on dysphoric disorders of PMS, helps to normalize the neuropsychological and cognitive state, to prevent of psychosomatic disorders.

Author Biographies

O. V. Gryshchenko, Kharkiv Medical Academy of Postgraduate Education, Kharkiv

MD, professor, head of the Perinatology, Obstetrics and Gynecology Department

V. V. Bobrytska, Kharkiv Medical Academy of Postgraduate Education, Kharkiv

PhD, associate professor, Perinatilogy, Obstetrics and Gynecology Department


  1. Andryushchenko, V.V., Lukavenko, I.M., Yazykov, O.V. “Laser–induced sclerotherapy of breast cysts.” Clinical surgery 1 (2017): 52–3.
  2. Bespalov, V.G. “Pathogenetic treatment of mastopathy and prevention of breast cancer.” Russian Medical Journal. Mother and child 2 (2018): 141–7.
  3. Bespalov, V.G., Negustorov, Y.F. “Mammographic density as a criterion for the effectiveness of treatment of mastopathy and reducing the risk of breast cancer.” Tumors of the female reproductive system 2 (2017): 33–41.
  4. Skurikhin, S.S., et al. “Vacuum-aspiration resection for focal dysplasia of the mammary gland.” Surgery. N.I. Pirogov Journal 2 (2018): 63–5.
  5. Vysotskaya, I.V., Letyagin, V.P. “Pharmacological effects and molecular mechanisms of action of a therapeutic phytopreparation based on Vitex agnus-castus.” Tumors of the female reproductive system 1 (2017): 14–9.
  6. Galganova, A.M., Petrov, Y.A. “Modern methods of diagnosis and treatment of hyperprolactinemia syndrome in women of reproductive age.” Modern problems of science and education 2 (2018). Available from: [–].
  7. Kornatska, A.G., et al. “Genetic risk factors for mastopathy in women with infertility.” Women's Health 1 (2016): 187–91.
  8. Dzhelomanova, O.A., Lasachko, S.A., Babich, T.Y. “Еffect of duration and features of lactation on the health of the mammary glands (literature review).” Modern medical technologies 4 (2010): 84–7.
  9. Zuykina, S.S., Vyshnevska, L.I. “Methodology of development of combined drugs based on medicinal plant raw materials for the treatment of mastopathy.” Management, economics and quality assurance in pharmacy 1.61 (2020): 6–12.
  10. Yefimenko, O.O., Mikhailenko, O.Y. “Hyperprolactinemia: interdisciplinary alliance.” Medical aspects of women's health 1 (2018): 34–8.
  11. Kerchelaeva, S.B., Smetnik, A.A., Bespalov, V.G. “Mastopathy and prevention of breast cancer as an interdisciplinary problem.” Russian medical journal 15 (2016): 1018–25.
  12. Kosei, N.V. “Correction of hormonal imbalance in patients with diffuse forms of mastopathy – the basis of pathogenetic therapy and prophylaxis.” Reproductive endocrinology 1(2018): 8–14.
  13. Kulagina, N.V. Phytotherapy of cyclic mastalgia in patients with diffuse mastopathy and premenstrual syndrome.” Meditsinsky Sovet 6 (2019): 136–40.
  14. Zapirova, S.B., et al. “The current classification and specific features of the clinic of roentgen sonopathomorphological manifestations of different forms of mastopathies.” Tumors of the female reproductive system 1–2 (2009): 10–5.
  15. Korzhenkova, G.P. “Diagnostic value of categories BI–RADS in the management of patients with benign breast pathology.” Tumors of the female reproductive system 12.4 (2016): 10–6.
  16. Makarenko, M.V., Govseev, D.O., Gromova, O.L., et al. “Features of hormonal hemostasis in patients with benign hyperplastic processes of the breasts.” Women's health 9.115 (2016): 72–4.
  17. Musina, E.V., Kogan, I.Y. “Mastopathy: pathogenesis and the possibility of correction.” Obstetrics and gynecology 10 (2016): 33–8.
  18. Potapov, V.A. “A multitarget approach to the treatment of fibrocystic mastopathy and the prevention of breast cancer.” Woman’s Health 1 (2016): 18–29.
  19. Pristash, Y.Y. “Hormonal status of patients in the course of surgical treatment of fibrous–cystic mastopathy and potency of the disease.” Woman's health 5 (2017): 128–31.
  20. Ruzhenkov, V.A., Shulichenko, E.A. “Mental disorders in women with benign breast dysplasia.” Modern problems of science and education 4 (2016). Available from: [].
  21. Smolanka, I.I. “Treatment of fibrocystic breast disease – a way to prevent breast cancer.” Reproductive endocrinology 2.22 (2015): 65–9.
  22. Syusyuka, V.G., et al. “Mastodynia in the context of breast diseases in women of reproductive age: an integrated approach to diagnosis and correction.” Health of Woman 6 (2016): 36–40.
  23. Travina, M.L., Popov, A.G. “Diseases of the mammary gland in the practice of obstetricians–gynecologists.” Health of Woman 2 (2016): 42–7.
  24. Beck, A.T., Epstein, N., Brown, G., Steer, R.A. “An inventory for measuring clinical anxiety: Psychometric properties.” Journal of Consulting and Clinical Psychology 56.6 (1988): 893–7.
  25. Bertone-Johnson, E.R., Houghton, S.C., Whitcomb, B.W., et al. “Association of Premenstrual Syndrome with Blood Pressure in Young Adult Women.” J Womens Health (Larchmt) 25.11 (2016): 1122–8.
  26. Czajkowska, M., Drosdzol–Cop, A., Galązka, I., et al. “Menstrual Cycle and the Prevalence of Premenstrual Syndrome / Premenstrual Dysphoric Disorder in Adolescent Athletes.” J Pediatr Adolesc Gynecol 28.6 (2015): 492–8.
  27. Damiano, J.S, Wasserman, E. “Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.” Clin Cancer Res 19 (2013): 1644–50.
  28. Jehan, Sh., August, E., Hussain, M., et al. “Sleep and Premenstrual Syndrome.” J Sleep Med Disord 3.5 (2016): 1061.
  29. Malherbe, K., Fatima, S. Fibrocystic Breast Disease. Treasure Island (FL). StatPearls Publishing (2020). Available from: [].
  30. Brkić, M., Vujović, S., Ivović, M., et al. “The role of E2/P ratio in the etiology of fibrocystic breast disease, mastalgia and mastodynia.” Acta Clin Croat 57.4 (2018): 756–61.
  31. Pereira, M.A., de Magalhães, A.V., da Motta, L.D., et al. “Fibrous mastopathy: clinical, imaging, and histopathologic findings of 31 cases.” J Obstet Gynaecol Res 36.2 (2010): 326–35.
  32. Seidlova–Wuttke, D., Wuttke, W. “The premenstrual syndrome, premenstrual mastodynia, fibrocystic mastopathy and infertility have often common roots: effects of extracts of chasteberry (Vitex agnus castus) as a solution.” Clin Phytosci 3.6 (2017). DOI: 10.1186/s40816-016-0038-z
  33. Takashi Takeda, Yoko Imoto, Hiroyo Nagasawa, et al. “Fish Consumption and Premenstrual Syndrome and Dysphoric Disorder in Japanese Collegiate Athletes.” J Pediatr Adolesc Gynecol 29.4 (2016): 386–9.
  34. Tikk, K., Sookthai, D., Johnson, T., et al. “Circulating prolactin and breast cancer risk among pre- and post-menopausal women in the EPIC cohort.” Ann Oncol 25 (2014): 1422–8.
  35. Thijssen, J.H.H. “Local biosynthesis and metabolism of oestrogens in the human breast.” Maturitas 49 (2004): 25–33.



How to Cite

Gryshchenko, O. V., & Bobrytska, V. V. (2020). Phytoselective therapy is a method of choice for the treatment of mastopathy in combination with premenstrual syndrome. REPRODUCTIVE ENDOCRINOLOGY, (55), 79–89.



Tumors and pretumoral pathology